BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20507361)

  • 1. Scleroderma: from pathophysiology to novel therapeutic approaches.
    Hunzelmann N; Krieg T
    Exp Dermatol; 2010 May; 19(5):393-400. PubMed ID: 20507361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models of scleroderma: lessons from transgenic and knockout mice.
    Derrett-Smith EC; Denton CP; Sonnylal S
    Curr Opin Rheumatol; 2009 Nov; 21(6):630-5. PubMed ID: 19730378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model.
    Chujo S; Shirasaki F; Kawara S; Inagaki Y; Kinbara T; Inaoki M; Takigawa M; Takehara K
    J Cell Physiol; 2005 May; 203(2):447-56. PubMed ID: 15605379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenic cytokines and growth factors in systemic sclerosis.
    Liakouli V; Cipriani P; Marrelli A; Alvaro S; Ruscitti P; Giacomelli R
    Autoimmun Rev; 2011 Aug; 10(10):590-4. PubMed ID: 21549861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis.
    Verrecchia F; Mauviel A; Farge D
    Autoimmun Rev; 2006 Oct; 5(8):563-9. PubMed ID: 17027893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma.
    Ludwicka A; Ohba T; Trojanowska M; Yamakage A; Strange C; Smith EA; Leroy EC; Sutherland S; Silver RM
    J Rheumatol; 1995 Oct; 22(10):1876-83. PubMed ID: 8991985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are the new milestones in the pathogenesis of systemic sclerosis?
    Hunzelmann N; Brinckmann J
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i52-56. PubMed ID: 19995745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of PDGF in fibrotic diseases and systemic sclerosis.
    Trojanowska M
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v2-4. PubMed ID: 18784131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.
    Reich N; Maurer B; Akhmetshina A; Venalis P; Dees C; Zerr P; Palumbo K; Zwerina J; Nevskaya T; Gay S; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2010 Jan; 62(1):280-90. PubMed ID: 20039427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis.
    Distler JH; Jüngel A; Pileckyte M; Zwerina J; Michel BA; Gay RE; Kowal-Bielecka O; Matucci-Cerinic M; Schett G; Marti HH; Gay S; Distler O
    Arthritis Rheum; 2007 Dec; 56(12):4203-15. PubMed ID: 18050252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways as novel therapeutic targets in systemic sclerosis.
    Trojanowska M; Varga J
    Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Connective tissue metabolism including cytokines in scleroderma.
    Smith EA
    Curr Opin Rheumatol; 1992 Dec; 4(6):869-77. PubMed ID: 1457283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and consequences of fibrosis in systemic sclerosis.
    Denton CP; Black CM; Abraham DJ
    Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Transforming growth factor-beta and its receptors in scleroderma].
    QIAN H; ZHENG M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):415-21. PubMed ID: 19693982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma.
    Shiwen X; Leask A; Abraham DJ; Fonseca C
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():19-26. PubMed ID: 19335743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of dermal connective tissue in scleroderma.
    Kähäri VM
    Ann Med; 1993 Dec; 25(6):511-8. PubMed ID: 8292298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines and human fibrosis.
    LeRoy EC; Trojanowska MI; Smith EA
    Eur Cytokine Netw; 1990; 1(4):215-9. PubMed ID: 1966552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Physiopathology of scleroderma].
    Fleischmajer R; Perlish JS; Maquart FX; Kalis B
    Ann Dermatol Venereol; 1993; 120(2):157-66. PubMed ID: 8363310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts.
    Mori Y; Chen SJ; Varga J
    Arthritis Rheum; 2003 Jul; 48(7):1964-78. PubMed ID: 12847691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta.
    Bhattacharyya S; Ghosh AK; Pannu J; Mori Y; Takagawa S; Chen G; Trojanowska M; Gilliam AC; Varga J
    Arthritis Rheum; 2005 Apr; 52(4):1248-58. PubMed ID: 15818659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.